Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.
Régis Peffault de LatourAustin KulasekararajSimona IacobelliSofie R TerwelRiley CookMorag GriffinConstantijn J M HalkesChristian RecherFiorenza BarracoEdouard ForcadeJuan-Carlos VallejoBeatrice DrexlerJean-Baptiste MearAlexander E SmithEmanuele AngelucciReinier A P RaymakersMarco R de GrootEtienne DaguindauErfan NurWilma BarcelliniNigel H RussellLouis TerriouAnna-Paola IoriUrsula La RoccaAnna SuredaIsabel Sánchez-OrtegaBlanca XicoyIsidro JarqueJames CavenaghFlore Sicre de FontbruneSerena MarottaTalha MunirJennifer M L TjonSuzanne TavitianAline PraireLaurence ClementFlorence RabianLuana MaranoAnita HillElena PalmisaniPetra MuusFabiana CacaceCamilla FrieriMaria-Teresa van LintJakob R PasswegJudith C W MarshGérard SociéGhulam J MuftiCarlo DufourAntonio M Risitanonull nullPublished in: The New England journal of medicine (2022)
The addition of eltrombopag to standard immunosuppressive therapy improved the rate, rapidity, and strength of hematologic response among previously untreated patients with severe aplastic anemia, without additional toxic effects. (Funded by Novartis and others; RACE ClinicalTrials.gov number, NCT02099747; EudraCT number, 2014-000363-40.).